In case you missed any, below is a recap of the episodes of OncLive On Air® that aired in July 2026. Check out our podcast page for a full episode lineup and to stay up to date with all the latest releases!
RECITE Findings Highlight the Potential of Romiplostim to Preserve Chemotherapy Delivery in GI Cancer: With Gerald Soff, MD
In this episode of OncLive On Air, Gerald Soff, MD, of the University of Miami Miller School of Medicine in Florida, discussed findings from the phase 3 RECITE trial (NCT03362177), which evaluated romiplostim for the management of chemotherapy-induced thrombocytopenia in patients with gastrointestinal cancers.
ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD
In this episode of Breast Cancer Briefing, host Sara Nunnery, MD, MSCI, of Tennessee Oncology in Nashville, was joined by MinhTri Nguyen, MD, of Rush MD Anderson Cancer Center in Chicago, Illinois, to discuss the emergence of giredestrant, an investigational oral selective estrogen receptor degrader, across the hormone receptor–positive, HER2-negative breast cancer paradigm.
How a Passion for Translational Research Fuses Surgery, Science, and Phase 1 Drug Development: With D. Ross Camidge, MD, PhD; and Funda Meric-Bernstam, MD
In this episode of How This Is Building Me, host D. Ross Camidge, MD, PhD, sat down with Funda Meric-Bernstam, MD, of The University of Texas MD Anderson Cancer Center in Houston, to trace her evolution from a science-focused student into a leader in precision oncology and early-phase drug development.
FDA Approval Insights: Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma: With Alex Herrera, MD
In this episode of OncLive On Air, Alex Herrera, MD, of City of Hope in Duarte, California, discussed the March 2026 FDA approval of nivolumab (Opdivo) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years of age and older with previously untreated stage III or IV classical Hodgkin lymphoma.
Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS
In this episode of OncLive On Air, Neil D. Gross, MD, FACS, of The University of Texas MD Anderson Cancer Center, discussed treatment selection and sequencing in advanced cutaneous squamous cell carcinoma.
DLBCL 2026 Update
In this episode, OncLive On Air partnered with Two Onc Docs—hosted by Samantha A. Armstrong, MD, of Indiana University Health in Indianapolis, and Karine Tawagi, MD, of the University of Illinois in Chicago—for a board-focused review of diffuse large B-cell lymphoma (DLBCL) for 2026.
Post-Breast Cancer Reconstruction Options Center Patient Preferences and Oncologic Expertise: With Sara Nunnery, MD, MSCI; Maelee Yang, MD; and Odette Abou Ghanem, MD
In this episode of Breast Cancer Briefing, Dr Nunnery was joined by Maelee Yang, MD, of The Surgical Clinic in Nashville, and Odette Abou Ghanem, MD, of Vanderbilt University Medical Center in Nashville, to discuss the breadth of breast reconstruction options for patients who have had breast cancer.
Treat Early and Aggressively: Optimizing Small Cell Lung Cancer Management Across the Community Setting: With Joshua K. Sabari, MD
In this episode of OncLive On Air, Joshua K. Sabari, MD, of NYU Langone Health’s Perlmutter Cancer Center in New York, New York, discussed management strategies for small cell lung cancer across academic and community settings.
FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Jorge E. Cortes, MD; and Elias Jabbour, MD
In this episode of OncLive On Air, Jorge E. Cortes, MD, of the UAB O’Neal Cancer Center in Birmingham, and Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, discussed the orally disintegrating tablet formulation of nilotinib (Cavhanza) and its June 2026 FDA approval for patients with chronic myeloid leukemia.
FDA Approval Insights: First-Line Sacituzumab Govitecan Plus Pembrolizumab for PD-L1+ TNBC: With Sara M. Tolaney, MD, MPH
In this episode of OncLive On Air, Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institute in Boston, Massachusetts, discussed the FDA approval of sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda) for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1.
ASCO 2026 ADC Data Clarify Some Strategies and Raise Further Questions for Breast Cancer Care: With Paolo Tarantino, MD, PhD
In this episode of OncLive On Air, Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute, discussed practice-informing antibody-drug conjugate data in breast cancer presented at the 2026 ASCO Annual Meeting (ASCO 2026).
FDA Approval Insights: Orca-T Raises the Bar for Allogeneic Transplants in Hematologic Malignancies: With Everett Meyer, MD, PhD
In this episode of OncLive On Air, Everett Meyer, MD, PhD, of Stanford Medicine in California, discussed the June 2026 FDA approval of allogeneic regulatory T cell–based immunotherapy with hematopoietic stem and progenitor cell and T cells-vldq (Tregzi; Orca-T) for use in matched donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, to improve chronic graft-vs-host disease–free survival in adults with hematologic malignancies.
Experts Bridge Oncology and Neurology to Catch LEMS Earlier in SCLC: With Misty D. Shields, MD, PhD; Triparna Sen, MD, PhD, MS; and Ditte Primdahl, MD
In this episode of OncLive On Air, an OncLive Peer Exchange discussion on cancer-associated Lambert-Eaton myasthenic syndrome (LEMS) was moderated by Misty D. Shields, MD, PhD, of the Indiana University School of Medicine in Indianapolis, who was joined by Triparna Sen, MD, PhD, MS, of The Ohio State University in Columbus, and Ditte Primdahl, MD, of the Northwestern University Feinberg School of Medicine in Chicago. The experts examined the ties between cancer-associated LEMS and small cell lung cancer, diagnostic challenges, treatment options for symptom control, and the importance of a multidisciplinary approach across oncology, neurology, and laboratory medicine for early LEMS diagnosis and effective management.
Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD
In this episode of OncLive On Air, Solange Peters, MD, PhD, of the University Hospital of Lausanne in Switzerland, discussed the rationale for pairing antiangiogenic activity with checkpoint inhibition upfront in non–small cell lung cancer (NSCLC), explained how PD-L1/VEGF bispecific antibodies like pumitamig broaden the eligible population compared with bevacizumab (Avastin)–based strategies, and described the mechanistic rationale for co-targeting VEGF and PD-L1.
Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD
In this episode of OncLive On Air, John N. Allan, MD, of Weill Cornell Medical College in New York, discussed a review he co-authored about the currently approved fixed-duration regimens for chronic lymphocytic leukemia.
Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD
In this episode of OncLive On Air, Tanios S. Bekaii-Saab, MD, of Mayo Clinic in Phoenix, Arizona, discussed findings from the final analysis of cohort 3 of the phase 3 BREAKWATER trial (NCT04607421) presented at ASCO 2026, highlighted promising bispecific agents targeting VEGF and PD-1, spoke about KRAS G12C inhibitors, and emphasized the prognostic and potentially predictive role of minimal residual disease testing in personalized metastatic colorectal cancer management.
Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD
In this episode of Oncology Unplugged, host Chandler Park, MD, of Norton Cancer Institute in Louisville, Kentucky, was joined by Stephen V. Liu, MD, of MedStar Georgetown University Hospital in Washington, DC, to discuss the continued evolution of precision medicine in non–small cell lung cancer and advances presented at ASCO 2026.
FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS
In this episode of OncLive On Air, Douglas W. Sborov, MD, MS, of the University of Utah Huntsman Cancer Institute in Salt Lake City, discussed the July 10, 2026, FDA approval of isatuximab-irfc (Sarclisa Escena) for subcutaneous injection across multiple myeloma indications—in combination with pomalidomide (Pomalyst) and dexamethasone; with carfilzomib (Kyprolis) and dexamethasone; and with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone.
